Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ...
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion. Bristol Myers Squibb agreed to a deal with Repertoire Immune Medicines in which it will pay $65 million ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...